ENTYVIO for CD

Results for Patients with Crohn's Disease

ENTYVIO helps control gastrointestinal (GI) inflammation that occurs in adults with moderate to severe Crohn's disease when certain other medicines have not worked well enough or cannot be tolerated.

In clinical studies, ENTYVIO was shown to help many patients achieve remission and without depending on steroids.

6 weeks
  • As early as Week 6, 15% of patients with Crohn's disease achieved remission compared to 7% of patients on placebo.

Long-Term
Remission Achieved

40 percent

Long-Term
Remission Achieved

  • 39% of patients with Crohn's disease achieved remission at one year compared to 22% of patients on placebo at 1 year.

Steroid-Free
Remission

2 times

Steroid-Free Remission

  • Twice as many patients with Crohn's disease taking ENTYVIO achieved remission without depending on steroids versus placebo at 1 year.

Individual results may vary.